BSE Live
Apr 17, 16:01Prev. Close
117.71
Open Price
117.68
Bid Price (Qty.)
121.00 (25)
Offer Price (Qty.)
125.15 (500)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Profit & Loss account of Godavari Drugs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 113.35 | 156.71 | 159.62 | 161.11 | 122.67 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 113.35 | 156.71 | 159.62 | 161.11 | 122.67 | |
| Total Operating Revenues | 113.35 | 156.71 | 159.62 | 161.11 | 122.67 | |
| Other Income | 0.98 | 0.62 | 0.66 | 0.28 | 0.41 | |
| Total Revenue | 114.33 | 157.33 | 160.28 | 161.38 | 123.08 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 85.24 | 121.95 | 137.82 | 127.97 | 94.15 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -3.58 | -1.14 | -9.76 | 2.48 | 2.44 | |
| Employee Benefit Expenses | 5.03 | 5.13 | 4.84 | 4.96 | 3.94 | |
| Finance Costs | 4.73 | 4.92 | 3.93 | 2.85 | 3.31 | |
| Depreciation And Amortisation Expenses | 2.45 | 1.99 | 1.94 | 1.70 | 1.22 | |
| Other Expenses | 14.84 | 17.47 | 16.81 | 14.40 | 12.31 | |
| Total Expenses | 108.70 | 150.32 | 155.57 | 154.36 | 117.37 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 5.63 | 7.01 | 4.71 | 7.02 | 5.71 | |
| Exceptional Items | 0.00 | -0.09 | 0.23 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 5.63 | 6.92 | 4.93 | 7.02 | 5.71 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 1.19 | 1.16 | 1.02 | 1.23 | 1.19 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.06 | 0.22 | 0.13 | 0.55 | 0.39 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 1.25 | 1.37 | 1.15 | 1.78 | 1.58 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 4.38 | 5.55 | 3.79 | 5.25 | 4.13 | |
| Profit/Loss From Continuing Operations | 4.38 | 5.55 | 3.79 | 5.25 | 4.13 | |
| Profit/Loss For The Period | 4.38 | 5.55 | 3.79 | 5.25 | 4.13 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | |
| Diluted EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 75.07 | 99.26 | 105.47 | 110.82 | 80.93 | |
| Indigenous Raw Materials | 10.17 | 22.69 | 32.35 | 17.16 | 13.22 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 1.98 | 1.70 | 1.83 | 1.78 | 1.84 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth